150 related articles for article (PubMed ID: 36244826)
1. Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer.
Garzon S; Grassi T; Mariani A; Kollikonda S; Weaver AL; McGree ME; Petersen IA; Weroha SJ; Glaser GE; Langstraat CL; Amarnath SR; AlHilli MM
Gynecol Oncol; 2022 Dec; 167(3):444-451. PubMed ID: 36244826
[TBL] [Abstract][Full Text] [Related]
2. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract][Full Text] [Related]
3. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
[TBL] [Abstract][Full Text] [Related]
4. Single-institutional outcomes of adjuvant brachytherapy for Stage I endometrial cancer-Are outcomes consistent with randomized studies?
Dohopolski MJ; Horne ZD; Gebhardt BJ; Glaser SM; Edwards RP; Kelley JL; Comerci JT; Olawaiye AB; Courtney-Brooks M; Berger JL; Sukumvanich P; Beriwal S
Brachytherapy; 2018; 17(3):564-570. PubMed ID: 29426745
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
Li JY; Park HS; Huang GS; Young MR; Ratner E; Santin A; Damast S
Gynecol Oncol; 2021 Dec; 163(3):557-562. PubMed ID: 34602287
[TBL] [Abstract][Full Text] [Related]
6. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
[TBL] [Abstract][Full Text] [Related]
7. Multi-institutional validation of the ESMO-ESGO-ESTRO consensus conference risk grouping in Turkish endometrial cancer patients treated with comprehensive surgical staging.
Gultekin M; Guler OC; Yuce Sari S; Akkus Yildirim B; Onal C; Celik H; Yuce K; Ayhan A; Arik Z; Kose F; Altundag O; Zoto Mustafayev T; Atalar B; Bolukbasi Y; Yildiz F
J Obstet Gynaecol; 2021 Apr; 41(3):414-420. PubMed ID: 32347768
[TBL] [Abstract][Full Text] [Related]
8. Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
Philp L; Tannenbaum S; Haber H; Saini A; Laurent JS; James K; Feltmate CM; Russo AL; Growdon WB
Gynecol Oncol; 2021 Feb; 160(2):389-395. PubMed ID: 33358198
[TBL] [Abstract][Full Text] [Related]
9. A novel low dose fractionation regimen for adjuvant vaginal brachytherapy in early stage endometrioid endometrial cancer.
Townamchai K; Lee L; Viswanathan AN
Gynecol Oncol; 2012 Nov; 127(2):351-5. PubMed ID: 22850411
[TBL] [Abstract][Full Text] [Related]
10. Impact of vaginal brachytherapy in intermediate and high-intermediate risk endometrial cancer: a multicenter study from the FRANCOGYN group.
Reboux PA; Azaïs H; Canova CH; Bendifallah S; Ouldamer L; Raimond E; Hudry D; Coutant C; Graesslin O; Touboul C; Collinet P; Bricou A; Huchon C; Daraï E; Ballester M; Lévêque J; Lavoué V; Koskas M; Uzan C; Canlorbe G
J Gynecol Oncol; 2019 Jul; 30(4):e53. PubMed ID: 31074238
[TBL] [Abstract][Full Text] [Related]
11. Low-Dose Adjuvant Cylinder Brachytherapy for Endometrioid Endometrial Cancer.
Alban GM; Buscariollo DL; Cheng T; Pretz J; Krechmer B; Buzurovic I; Singer L; King M; Lee L
Pract Radiat Oncol; 2020; 10(2):95-103. PubMed ID: 31783169
[TBL] [Abstract][Full Text] [Related]
12. Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients.
Röper B; Astner ST; Heydemann-Obradovic A; Thamm R; Jacob V; Hölzel D; Schmalfeldt B; Kiechle-Bahat M; Höss C; Molls M
Gynecol Oncol; 2007 Dec; 107(3):541-8. PubMed ID: 17884152
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer.
Dunn EF; Geye H; Platta CS; Gondi V; Rose S; Bradley KA; Anderson BM
Gynecol Oncol; 2014 Jun; 133(3):494-8. PubMed ID: 24657301
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.
Son J; Chambers LM; Carr C; Michener CM; Yao M; Beavis A; Yen TT; Stone RL; Wethington SL; Fader AN; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan A; Ricci S
Int J Gynecol Cancer; 2020 Nov; 30(11):1738-1747. PubMed ID: 32771986
[TBL] [Abstract][Full Text] [Related]
15. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
van den Heerik ASVM; Horeweg N; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld GH; van den Berg HA; Slot A; Koppe FLA; Kommoss S; Mens JWM; Nowee ME; Bijmolt S; Cibula D; Stam TC; Jurgenliemk-Schulz IM; Snyers A; Hamann M; Zwanenburg AG; Coen VLMA; Vandecasteele K; Gillham C; Chargari C; Verhoeven-Adema KW; Putter H; van den Hout WB; Wortman BG; Nijman HW; Bosse T; Creutzberg CL
Int J Gynecol Cancer; 2020 Dec; 30(12):2002-2007. PubMed ID: 33046573
[TBL] [Abstract][Full Text] [Related]
16. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer.
Jin M; Hou X; Sun X; Zhang Y; Hu K; Zhang F
Int J Gynecol Cancer; 2019 Oct; 29(8):1264-1270. PubMed ID: 31320487
[TBL] [Abstract][Full Text] [Related]
17. Vaginal brachytherapy alone for patients with Stage II endometrial cancer with inner half cervical stromal invasion.
Barnes EA; Parra-Herran C; Martell K; Barbera L; Taggar A; Leung E
Brachytherapy; 2019; 18(5):606-611. PubMed ID: 31200993
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Pelvic Radiation Therapy±Vaginal Brachytherapy in Patients With High-risk Stage I or Stage II Uterine Papillary Serous, Clear Cell, and High-grade Endometrioid Carcinoma.
Nagar H; Yan W; Parashar B; Nori D; Chao KS; Christos P; Gupta D; Holcomb K; Caputo T; Wernicke AG
Am J Clin Oncol; 2016 Aug; 39(4):335-9. PubMed ID: 27028349
[TBL] [Abstract][Full Text] [Related]
19. Impact of vaginal brachytherapy on survival in stage I endometrioid endometrial carcinoma.
AlHilli M; Amarnath S; Elson P; Rybicki L; Dowdy S
Int J Gynecol Cancer; 2020 Jun; 30(6):789-796. PubMed ID: 32184268
[TBL] [Abstract][Full Text] [Related]
20. External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer.
Lin LL; Mutch DG; Rader JS; Powell MA; Grigsby PW
Gynecol Oncol; 2007 Jul; 106(1):215-20. PubMed ID: 17482665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
